RB1 and cancer: To determine the frequency of TP53/RB1 co‐alterations across various tumors, we analyzed somatic mutation data and copy number variation data from 42 371 pan‐cancer samples spanning 26 distinct cancer types, covering malignancies of the respiratory, digestive, reproductive, and urinary systems, among others (Figure 1A; Table 1).